Neurocrine Biosciences Inc.

Neurocrine Biosciences develops and markets therapies for disorders, featuring INGREZZA for Huntington’s disease‐related dyskinesia and Orilissa for endometriosis. Its expanding pipeline tackles Parkinson’s, schizophrenia and depression, supported by Takeda, AbbVie and others.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 1,800
HQ: San Diego

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
NBIX	Neurocrine Biosciences Inc. Cap: 13.5B \| P/E: 32.4	EQUITY	NMS	USD	US64125C1099	Active	📈